Skip to main content
SpringerLink
Log in

Secondary prevention of hip fractures should be standard care for patients who sustain a hip fracture

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. British National Formulary. No. 43. London: The Pharmaceutical Press, 2002 Mar

  2. Kamel HC, Duthie EH. The underuse of therapy in the secondary prevention of hip fractures. Drugs Aging; 19 (1): 1–10

  3. NIH Consensus conference. Optimal calcium intake: NIH consensus development panel on optimal calcium intake. JAMA 1994; 272 (24): 1942–8

    Article  Google Scholar 

  4. Cooper C, Campion G, Melton III LJ. Hip fractures in the elderly: a worldwide projection. Osteoporosis Int 1992; 2 (6): 285–9

    Article  CAS  Google Scholar 

  5. Ray NF, Chan JF, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporotic Foundation. J Bone Miner Res 1997; 12: 24–35

    Article  PubMed  CAS  Google Scholar 

  6. Gardsell, P, Johnell O, Nillson BE. The predictive value of forearm bone mineral content measurements in men. Bone 1990; 11: 229–32

    Article  PubMed  CAS  Google Scholar 

  7. Melton LJ, Ilstrup DM, Beckenbaugh RD, et al. Hip fracture recurrence: a population-based study. Clin Orthop 1982; 167: 131–8

    PubMed  Google Scholar 

  8. Chestnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporosis study. Am J Med 2000; 109: 267–76

    Article  Google Scholar 

  9. Ettinger B, Blacm DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282 (7): 637–45

    Article  PubMed  CAS  Google Scholar 

  10. Chapuy MC, Arlot ME, Duboef F, et al. Vitamin D3, and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42

    Article  PubMed  CAS  Google Scholar 

  11. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6

    Article  PubMed  CAS  Google Scholar 

  12. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282 (14): 1344–52

    Article  PubMed  CAS  Google Scholar 

  13. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344 (5): 333–40

    Article  PubMed  CAS  Google Scholar 

  14. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348 (9041): 1535–41

    Article  PubMed  CAS  Google Scholar 

  15. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–80

    Article  PubMed  CAS  Google Scholar 

  16. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9–16

    PubMed  CAS  Google Scholar 

  17. Michaelsson K, Baron JA, Johnell O, et al. Variation in the efficacy of hormone replacement therapy in the prevention of hip fractures. Swedish Hip Fracture Study Group. Osteoporosis Int 1998; 8 (6): 540–6

    Article  CAS  Google Scholar 

  18. Gillespie WJ, Avenell A, Henry DA, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Sys Rev 2001; 1:CD000227

    Google Scholar 

  19. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–41

    Article  PubMed  CAS  Google Scholar 

  20. Lauitzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11–3

    Article  Google Scholar 

  21. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev 2001; 2: CD001255

    Google Scholar 

  22. Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fractures. Am J Med 2000; 109: 326–8

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Secondary prevention of hip fractures should be standard care for patients who sustain a hip fracture. Drugs Ther. Perspect 19, 14–17 (2003). https://doi.org/10.2165/00042310-200319010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319010-00005

Keywords

Search

Navigation